BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 27846227)

  • 21. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
    Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
    J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transarterial chemoembolization versus surgery/radiofrequency ablation for recurrent hepatocellular carcinoma with or without microvascular invasion.
    Jin YJ; Lee JW; Lee OH; Chung HJ; Kim YS; Lee JI; Cho SG; Jeon YS; Lee KY; Ahn SI; Shin WY
    J Gastroenterol Hepatol; 2014 May; 29(5):1056-64. PubMed ID: 24372785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of survival of patients with BCLC stage A hepatocellular carcinoma after hepatic resection or transarterial chemoembolization: a propensity score-based analysis.
    Guo Z; Zhong JH; Jiang JH; Zhang J; Xiang BD; Li LQ
    Ann Surg Oncol; 2014 Sep; 21(9):3069-76. PubMed ID: 24728740
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monofocal hepatocellular carcinoma: How much does size matter?
    Pelizzaro F; Penzo B; Peserico G; Imondi A; Sartori A; Vitale A; Cillo U; Giannini EG; Forgione A; Ludovico Rapaccini G; Di Marco M; Caturelli E; Zoli M; Sacco R; Cabibbo G; Marra F; Mega A; Morisco F; Gasbarrini A; Svegliati-Baroni G; Giuseppe Foschi F; Olivani A; Masotto A; Nardone G; Raimondo G; Azzaroli F; Vidili G; Oliveri F; Trevisani F; Farinati F;
    Liver Int; 2021 Feb; 41(2):396-407. PubMed ID: 33155401
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Surgical resection versus transarterial chemoembolization for BCLC stage C hepatocellular carcinoma.
    Liu PH; Hsia CY; Lee YH; Hsu CY; Huang YH; Su CW; Lee RC; Lin HC; Huo TI
    J Surg Oncol; 2015 Mar; 111(4):404-9. PubMed ID: 25643842
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study.
    Vitale A; Morales RR; Zanus G; Farinati F; Burra P; Angeli P; Frigo AC; Del Poggio P; Rapaccini G; Di Nolfo MA; Benvegnù L; Zoli M; Borzio F; Giannini EG; Caturelli E; Chiaramonte M; Trevisani F; Cillo U;
    Lancet Oncol; 2011 Jul; 12(7):654-62. PubMed ID: 21684210
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Proposal for Modification of the Barcelona Clinic Liver Cancer Staging System Considering the Prognostic Implication of Performance Status.
    Cho HJ; Kim SS; Kang SY; Yang MJ; Noh CK; Hwang JC; Lim SG; Shin SJ; Lee KM; Yoo BM; Lee KJ; Kim JH; Cho SW; Cheong JY;
    Gut Liver; 2019 Sep; 13(5):557-568. PubMed ID: 31023007
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Performance status in patients with hepatocellular carcinoma: determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system.
    Hsu CY; Lee YH; Hsia CY; Huang YH; Su CW; Lin HC; Lee RC; Chiou YY; Lee FY; Huo TI
    Hepatology; 2013 Jan; 57(1):112-9. PubMed ID: 22806819
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Barcelona Clinic Liver Cancer staging system and survival of untreated hepatocellular carcinoma in a hepatitis B virus endemic area.
    Lee JH; Kim HY; Kim YJ; Yoon JH; Chung JW; Lee HS
    J Gastroenterol Hepatol; 2015 Apr; 30(4):696-705. PubMed ID: 25250761
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Validation and modification of a proposed substaging system for patients with intermediate hepatocellular carcinoma.
    Wang JH; Kee KM; Lin CY; Hung CH; Chen CH; Lee CM; Lu SN
    J Gastroenterol Hepatol; 2015 Feb; 30(2):358-63. PubMed ID: 25088668
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Survival analysis of proposed BCLC-B subgroups in hepatocellular carcinoma patients.
    Weinmann A; Koch S; Sprinzl M; Kloeckner R; Schulze-Bergkamen H; Düber C; Lang H; Otto G; Wörns MA; Galle PR
    Liver Int; 2015 Feb; 35(2):591-600. PubMed ID: 25290314
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Validation of a Modified Substaging System (Kinki Criteria) for Patients with Intermediate-Stage Hepatocellular Carcinoma.
    Arizumi T; Ueshima K; Iwanishi M; Minami T; Chishina H; Kono M; Takita M; Kitai S; Inoue T; Yada N; Hagiwara S; Ida H; Minami Y; Sakurai T; Kitano M; Nishida N; Kudo M
    Oncology; 2015; 89 Suppl 2():47-52. PubMed ID: 26584036
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective validation of the Barcelona Clinic Liver Cancer staging system.
    Cillo U; Vitale A; Grigoletto F; Farinati F; Brolese A; Zanus G; Neri D; Boccagni P; Srsen N; D'Amico F; Ciarleglio FA; Bridda A; D'Amico DF
    J Hepatol; 2006 Apr; 44(4):723-31. PubMed ID: 16488051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma.
    Giannini EG; Moscatelli A; Pellegatta G; Vitale A; Farinati F; Ciccarese F; Piscaglia F; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Cabibbo G; Felder M; Sacco R; Morisco F; Missale G; Foschi FG; Gasbarrini A; Baroni GS; Virdone R; Masotto A; Trevisani F; ;
    Am J Gastroenterol; 2016 Jan; 111(1):70-7. PubMed ID: 26729544
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre.
    Grieco A; Pompili M; Caminiti G; Miele L; Covino M; Alfei B; Rapaccini GL; Gasbarrini G
    Gut; 2005 Mar; 54(3):411-8. PubMed ID: 15710992
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system.
    Han K; Kim JH
    World J Gastroenterol; 2015 Sep; 21(36):10327-35. PubMed ID: 26420959
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BCLC stage B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20-year survey by the Italian Liver Cancer group.
    Farinati F; Vanin V; Giacomin A; Pozzan C; Cillo U; Vitale A; Di Nolfo AM; Del Poggio P; Benvegnu' L; Rapaccini G; Zoli M; Borzio F; Giannini EG; Caturelli E; Trevisani F;
    Liver Int; 2015 Jan; 35(1):223-31. PubMed ID: 25074434
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma.
    Wang JH; Wang CC; Hung CH; Chen CL; Lu SN
    J Hepatol; 2012 Feb; 56(2):412-8. PubMed ID: 21756858
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for hepatocellular carcinoma.
    Ni JY; Sun HL; Chen YT; Luo JH; Chen D; Jiang XY; Xu LF
    World J Gastroenterol; 2014 Dec; 20(46):17483-90. PubMed ID: 25516662
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Different survival of Barcelona clinic liver cancer stage C hepatocellular carcinoma patients by the extent of portal vein invasion and the type of extrahepatic spread.
    Sinn DH; Cho JY; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    PLoS One; 2015; 10(4):e0124434. PubMed ID: 25923439
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.